These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7384091)

  • 1. Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
    Isaacs JT; Weissman RM; Coffey DS; Scott WW
    Prog Clin Biol Res; 1980; 37():311-23. PubMed ID: 7384091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.
    Isaacs JT; Heston WD; Weissman RM; Coffey DS
    Cancer Res; 1978 Nov; 38(11 Pt 2):4353-9. PubMed ID: 698976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
    Smolev JK; Heston WD; Scott WW; Coffey DS
    Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology, histochemistry, and acid phosphatase of Noble (Nb) rat prostate adenocarcinomas and treatment of an androgen-dependent Nb rat prostate adenocarcinoma.
    Drago JR; Goldman LB; Maurer RE; Eckels DD; Gershwin ME
    J Natl Cancer Inst; 1980 Apr; 64(4):931-7. PubMed ID: 6929004
    [No Abstract]   [Full Text] [Related]  

  • 5. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.
    Isaacs JT; Yu GW; Coffey DS
    Invest Urol; 1981 Jul; 19(1):20-3. PubMed ID: 7251319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
    Ellis WJ; Isaacs JT
    Cancer Res; 1985 Dec; 45(12 Pt 1):6041-50. PubMed ID: 4063963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rat prostatic adenocarcinoma as a model for the human disease.
    Müntzing J; Kirdani RY; Murphy GP; Sandberg AA
    Invest Urol; 1979 Jul; 17(1):37-41. PubMed ID: 447485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine manipulation of the Dunning prostatic adenocarcinoma.
    Shessel FS; Block NL; Stover B; Claflin A; Malinin TI; Politano VA
    Invest Urol; 1980 May; 17(6):529-33. PubMed ID: 7372443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
    Tomura A; Kuroiwa S; Okada M; Abe F
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
    Isaacs JT
    Cancer Res; 1982 Dec; 42(12):5010-4. PubMed ID: 6215981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
    Lowe FC; Isaacs JT
    Cancer Res; 1984 Feb; 44(2):744-52. PubMed ID: 6537899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An animal model for the study of prostate carcinoma.
    Lubaroff DM; Canfield L; Rasmussen GT; Reynolds CW
    Natl Cancer Inst Monogr; 1978 Dec; (49):275-81. PubMed ID: 748781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with an animal model for the study of prostatic carcinoma.
    Lubaroff DM; Culp DA
    Trans Am Assoc Genitourin Surg; 1977; 69():72-7. PubMed ID: 617916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Models for development of nonreceptor methods for distinguishing androgen-sensitive and -insensitive prostatic tumors.
    Isaacs JT; Isaacs WB; Coffey DS
    Cancer Res; 1979 Jul; 39(7 Pt 1):2652-9. PubMed ID: 445468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
    Brändström A; Westin P; Bergh A; Cajander S; Damber JE
    Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for an idealized animal model of prostatic cancer.
    Coffey DS; Isaacs JT
    Prog Clin Biol Res; 1980; 37():379-91. PubMed ID: 7384094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of castration, testosterone and oestrogen on epithelial and stromal growth and morphology of the Dunning (R3327H) prostatic adenocarcinoma.
    Damber JE; Landström M; Bergh A; Tomic R
    Scand J Urol Nephrol Suppl; 1988; 110():145-8. PubMed ID: 3187402
    [No Abstract]   [Full Text] [Related]  

  • 18. Purification and characterization of acid phosphatase from Dunning R3327H prostatic adenocarcinoma.
    Lee C; Murphy GP; Chu TM
    Cancer Res; 1980 Apr; 40(4):1245-8. PubMed ID: 7357554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dunning tumors.
    Lubaroff DM; Canfield L; Reynolds CW
    Prog Clin Biol Res; 1980; 37():243-63. PubMed ID: 6247719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.